Cv Therapeutics, Inc.

Gilead Palo Alto, Inc.

Gilead Sciences, Inc.

Other

Vaibhav Varkhedkar

Jeff A Zablocki

Venkata Poornapragnacharyulu Palle

Prabha N Ibrahim

Elfatih O Elzein

Dengming Xiao

Rao V Kalla

Thao Perry

Xiaofen Li

Arvinder Dhalla

Luiz Belardinelli

Brent K Blackburn

Elfaith O Elzein

Venkata P Palle

Luiz Belardenelli

Venkata Palle

Venkata D-011 Oakwood Estates Palle

Disclosed are novel compounds that are Aadenosine receptor antagonists, useful for treating various disease states, including asthma and diarrhea.

[object Object]

Disclosed are novel compounds a compound of Formula I that are partial and full Aadenosine receptor agonists, useful for treating various disease states, in particular dyslipidemia, diabetes, decreased insulin sensitivity, Polycystic Ovarian Syndrome, Stein-Leventhal syndrome, and obesity.

Disclosed are novel Aadenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

A2B adenosine receptor antagonists

Disclosed are novel compounds that are partial and full Aadenosine receptor agonists, useful for treating various disease states, in particular tachycardia and atrial flutter, angina, and myocardial infarction.

Disclosed are novel Aadenosine receptor antagonists having the structure of Formula I or Formula II The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

Disclosed are novel compounds that are Aadenosine receptor agonists, useful for treating various disease states, including cancer, cardiac ischemia, leukopenia, and neutropennia.

Disclosed are novel Aadenosine receptor antagonists of Formula I: wherein:

Partial and full agonists of A1 adenosine receptors

Disclosed are methods for making novel Aadenosine receptor antagonists having the structure of formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

Disclosed are novel Aadenosine receptor antagonists having the structure of Formula I or Formula II:The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.

Growing community of inventors

San Diego, CA, United States of America

Vaibhav Varkhedkar